



Drugs Repurposing for Multi-Drug Resistant Bacterial Infections

Guest Editors:

Dr. Maytham Hussein

Faculty of Medicine, Dentistry
and Health Sciences, Melbourne,
Australia

Dr. Tony Velkov

Monash Biomedicine Discovery
Institute, Department of
Microbiology, Monash University,
Clayton, VIC 3800, Australia

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

Multidrug-resistant (MDR) bacteria are becoming a major burden for public health systems worldwide. The excessive and inappropriate use of antibiotics following antibiotic discoveries has led to the development of numerous MDR bacteria. This issue is further compounded by the exodus of many pharmaceutical companies from the antibiotics discovery industry due to lengthy and unreliable product development processes and low economic returns. In order to prevent resistance against conventional antibiotics, novel application approaches need to be considered as the development of new antibiotics is still beyond the horizon. Combining antibiotic and non-antibiotic drugs for improved efficacy and to delay the inevitable development of bacterial resistance has thus emerged as a cost-effective approach to fighting MDR bacteria.

We welcome the submission of reviews, opinions, and original research focusing on drug re-purposing for treatment against bacteria.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Hinh Ly

Department of Veterinary &
Biomedical Sciences, University
of Minnesota, Twin Cities, MN,
USA

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)